Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | PLK4 | O00444 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | PAK4 | O96013 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | PRKCG | P05129 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | LYN | P07948 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5383817 | 0.82 | IRAK4 (0.41) | IRAK4AURKAPIM1CDC7PLK4 | |
| SCHEMBL5375104 | 0.82 | HSD17B10 (0.40) | ROCK2MAPK1ROCK1MEN1KMT2A | |
| SCHEMBL5371605 | 0.81 | ALDH1A1 (0.41) | CDC7MARK3MAPK1STK3MEN1 | |
| SCHEMBL5372887 | 0.81 | ALDH1A1 (0.43) | IRAK4MAPK1IRAK1CNR2LMNA | |
| SCHEMBL5374769 | 0.79 | AURKA (0.40) | IRAK4AURKAPIM1CDC7PLK4 | |
| SCHEMBL5369627 | 0.76 | MAPK1 (0.37) | IRAK4AURKAPIM1CDC7PLK4 | |
| SCHEMBL5369630 | 0.76 | CNR2 (0.38) | IRAK4AURKAPIM1CDC7PLK4 | |
| SCHEMBL5378536 | 0.73 | PRKDC (0.38) | IRAK4AURKAPIM1CDC7PLK4 | |
| SCHEMBL5378305 | 0.69 | AVPR1A (0.40) | IRAK4IRAK1ABL1CNR2 | |
| SCHEMBL5366214 | 0.68 | KDM4E (0.41) | CDC7CHEK1LCKFYNFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7238212-B2 | Imidazole compounds and use of these compounds for dyeing keratinous fibers | L'OREAL, S.A. (FR) | 2007-07-03 | — | — | US | claimed |
| US-20050011019-A1 | Novel imidazole compounds and use of these compounds for dyeing keratinous fibers | L'OREAL, S.A. (FR) | 2005-01-20 | — | — | US | claimed |
| EP-1484049-A1 | Imidazole compounds and their use for dyeing of keratinous fibres | L'OREAL (FR) | 2004-12-08 | — | — | EP | claimed |
| US-7238212-B2 | Imidazole compounds and use of these compounds for dyeing keratinous fibers | L'OREAL, S.A. (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20050011019-A1 | Novel imidazole compounds and use of these compounds for dyeing keratinous fibers | L'OREAL, S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| EP-1484049-A1 | Imidazole compounds and their use for dyeing of keratinous fibres | L'OREAL (FR) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050011019-A1 | Novel imidazole compounds and use of these compounds for dyeing keratinous fibers | KRT18, VIM, NDUFS6 | IRAK4 2412/4885AURKA 1343/4885PIM1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.